Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Other Financing Activities

Financing cash flows not reported separately.

Atai Beckley Inc.NASDAQ: ATAI

Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026

Other financing activities turns positive

Q2 FY2026 other financing activities was $11.21K, compared with -$8.46M a year earlier. Trailing-twelve-month other financing activities was -$6.24M.

Context

  • Other financing activities amounted to 529.8% of revenue in FY2025, up 477.5 pp from a year earlier.
  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near $11.21K or moves back toward the trailing-twelve-month quarterly average of -$1.56M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$11.21K— QoQ
Last fiscal yearDec 2025
-$21.66M+13355.3% YoY
LTMJun 2026
-$6.24M-26.9% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.1%——
1 year+13355.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(21.66M) USD
Year-over-year change
-13355.3%

Other Financing Activities vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.9% is the 2nd highest of 9, against a peer median of -99.3%.
  • Other financing activities amounts to 139.5% of revenue for ATAI, versus a peer median of 2.7%.
ATAI Competitors
Other Financing Activities for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$964.79M USD+202585.9%—50671.5%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$267.49M USD-528.8%+72.2%—
ATAIAtai Beckley Inc.LTM Jun 2026$6.24M USD-26.9%—139.5%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$2.74M USD-97.0%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$1.61M USD———
IMTXImmatics N.V.LTM Mar 2026€1.5M EUR-84.6%-29.0%4.0%
NKTRNektar TherapeuticsLTM Jun 2026$784K USD——1.4%
SANASana Biotechnology, Inc.LTM Mar 2026$551K USD-99.7%——
INBXInhibrx Biosciences, Inc.LTM Mar 2026$352K USD-98.9%—27.1%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$0 USD-100.0%—0.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding ATAI) —-99.3%+21.6%2.7%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.24M)(157.42M)(43.9M)(150.05M)(660.05M)
Depreciation & Amortization47K168K319K473K1.01M
Deferred Income Tax39.14M5.07M000
Stock-Based Compensation63.36M42.38M32.98M25.49M0
Change in Working Capital(7.6M)(3.34M)7.47M(9.2M)(6.48M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.3M(3.03M)2.14M(1.87M)(1.7M)
Other Working Capital(9.9M)(301K)5.33M(7.33M)(4.78M)
Other Non-Cash Items16.06M8.67M(80.99M)50.85M562.84M
Operating Cash Flow(63.25M)(104.47M)(84.12M)(82.44M)(102.68M)
Capital Expenditures(1.13M)(1.02M)(590K)(95K)(901K)
Acquisitions (Net)(52.94M)0(443K)359K4.64M
Purchases of Investments(23.66M)(309.66M)(186.22M)(15M)(98.95M)
Sales of Investments(955K)226.83M139.47M82.01M9.05M
Other Investing Activities(2.6M)(3.25M)(5.84M)(8.1M)(13M)
Investing Cash Flow(81.28M)(86.85M)(53.3M)59.17M(109.13M)
Debt Repayment1.59M15M05M7.71M
Common Stock Issued409.88M00535K283.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.42M5.19M(8.36M)(161K)(21.66M)
Financing Cash Flow409.86M20.79M(8.36M)5.37M269.48M
Effect of Forex Changes(320K)(1.12M)189K362K116K
Net Change in Cash265.02M(171.65M)(145.58M)(17.53M)57.8M
Free Cash Flow(64.37M)(105.49M)(84.71M)(82.53M)(103.58M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.